Fibromyalgia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Fibromyalgia – Pipeline Review, H2 2017’, provides an overview of the Fibromyalgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibromyalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Fibromyalgia

The report reviews pipeline therapeutics for Fibromyalgia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Fibromyalgia therapeutics and enlists all their major and minor projects

The report assesses Fibromyalgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Fibromyalgia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Fibromyalgia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Daiichi Sankyo Company Ltd

Immune Therapeutics Inc

Innovative Med Concepts LLC

Intec Pharma ltd

Jiangsu Hengrui Medicine Co Ltd

KPI Therapeutics Inc

Merck & Co Inc

Pfizer Inc

Switch Biotech LLC

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fibromyalgia - Overview

Fibromyalgia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibromyalgia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibromyalgia - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Daiichi Sankyo Company Ltd

Immune Therapeutics Inc

Innovative Med Concepts LLC

Intec Pharma ltd

Jiangsu Hengrui Medicine Co Ltd

KPI Therapeutics Inc

Merck & Co Inc

Pfizer Inc

Switch Biotech LLC

Zynerba Pharmaceuticals Inc

Fibromyalgia - Drug Profiles

(cannabidiol + dronabinol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(celecoxib + famciclovir) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-1069562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-8062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirogabalin besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirtazapine ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SWT-06101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibromyalgia - Dormant Projects

Fibromyalgia - Discontinued Products

Fibromyalgia - Product Development Milestones

Featured News & Press Releases

Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes

Jun 26, 2017: Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program

Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201, a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia

Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN001

Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin

Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study

Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin

Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia

Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica’s Discontinuation Effects In Patients With Generalized Anxiety Disorder

Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Fibromyalgia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Fibromyalgia – Pipeline by Astellas Pharma Inc, H2 2017

Fibromyalgia – Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Fibromyalgia – Pipeline by Immune Therapeutics Inc, H2 2017

Fibromyalgia – Pipeline by Innovative Med Concepts LLC, H2 2017

Fibromyalgia – Pipeline by Intec Pharma ltd, H2 2017

Fibromyalgia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Fibromyalgia – Pipeline by KPI Therapeutics Inc, H2 2017

Fibromyalgia – Pipeline by Merck & Co Inc, H2 2017

Fibromyalgia – Pipeline by Pfizer Inc, H2 2017

Fibromyalgia – Pipeline by Switch Biotech LLC, H2 2017

Fibromyalgia – Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Fibromyalgia – Dormant Projects, H2 2017

Fibromyalgia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Fibromyalgia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Fibromyalgia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports